Study of Physical Activity and Nutrition to Reduce Neurotoxicity in Adults with Hematologic Cancer Receiving CAR-T Therapy
Led by Instituto de Investigacion Sanitaria INCLIVA · Updated on 2026-07-28
338
Participants Needed
2
Research Sites
61 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two non-drug approaches to reduce neurotoxicity caused by CAR-T cell therapy in adults aged 18 to 80 years with hematologic cancer. The study aims to determine whether a structured physical activity program alone or combined with nutritional recommendations can better lower the risk or severity of neurotoxicity compared to no intervention. This trial is a randomized, multicenter controlled study conducted between July 2025 and July 2027.
Participants will be randomly assigned to one of three groups a physical activity program, a combined physical activity and Mediterranean diet-based nutritional program, or a control group receiving no intervention. The exercise program includes aerobic and resistance sessions supervised by physiotherapists, adapted to the participants fitness level. Nutritional guidance emphasizes anti-inflammatory and antioxidant-rich foods. Interventions start one month before CAR-T therapy and continue at least one month after treatment.
Participants will be monitored weekly before, during, and for four weeks after CAR-T therapy by a multidisciplinary team. Assessments include neurotoxicity severity, physical activity levels, nutritional status, functional independence, quality of life, and adherence to interventions. Evaluations occur at baseline, during treatment, and post-treatment for up to 15 days after CAR-T therapy. Comprehensive symptom and health data will be collected throughout the study, which is sponsored by Instituto de Investigacion Sanitaria INCLIVA.
CONDITIONS
Brief Title
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
Research Team
M
Marina Hernandez Aliaga, RN, MSc, PhD(c)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Starting antineoplastic treatment with CAR-T cell therapy
You will not qualify if you...
Language barriers or physical/cognitive impairments preventing understanding or completion of study assessments
Existing neurological or psychiatric conditions that interfere with neurotoxicity evaluation
Receiving additional neurotoxic drugs unrelated to the study protocol
History of abusive consumption of neurotoxic substances
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Intervention and Monitoring
Duration - Approximately 3 months total
Participants follow their assigned program: physical activity alone, physical activity combined with nutritional guidance, or no intervention. The program starts at least one month before CAR-T therapy and continues for at least one month after treatment. Weekly evaluations by a multidisciplinary team are conducted before, during, and for four weeks after CAR-T therapy.
Weekly visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Similar Trials
Evaluating Venetoclax Addition to Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation in Patients With Chronic Kidney Disease and Blood Cancers
Study of Immune Factors Affecting Response and Side Effects of Adoptive Cell Therapy in Solid and Blood Cancers
Comprehensive Molecular Profiling and Clinical Data Analysis for Cancer Patients and Those at Risk in a Community Healthcare Setting
Study on Stopping Maintenance Therapy in Adults with Multiple Myeloma Who Have Achieved Stable Minimal Residual Disease Negative Remission Without High-Risk Factors
Monitoring for Early Signs of Complications During Immunotherapy in Blood Cancers
Using Vital Sign Tracking and Immune Response Analysis
Hypnosis for Anxiety Relief in Adults with Hematologic Cancer
Focusing on Patients with Diffuse Large B-Cell or Follicular Lymphoma
Starting Hypnotherapy Within 2 Months of Diagnosis
Improving Care for Adults with Breast, Gastrointestinal, or Hematologic Cancer and Other Health Conditions
Using a Shared Care Model Between Oncologists and Primary Care Providers
Study of Physical Activity and Nutrition to Reduce Neurotoxicity in Adults with Hematologic Cancer Receiving CAR-T Therapy
Genetic Study of Blood Cancers Using Online Surveys and Saliva Samples by Rutgers University
SURGE Enhancing Genomic Testing Access and Representation in Cancer Clinical Trial Enrollment Through Video and Patient Navigation Support
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The Effect of Exercise-Based Interventions on Health-Related Quality of Life of Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis.
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis.